ABVD versus BEACOPP for Hodgkin's Lymphoma

Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma

“…However, the ABVD regimen exhibited the lowest toxicity rates. ABVD is the most widely used regimen for advanced HL patients ( Corazzelli et al, 2011 ). After the MOPP regimen, ABVD was superior to or less toxic than non-cross-resistant alternating regimens (MOPP + ABVD and MOPP + ABV), multidrug regimens (MOPP) and chemoradiotherapy (Stanford V) ( Ansell, 2016 ; Carde et al, 2016 ).…”

“…The MOPP (mechlorethamine + vincristine + procarbazine + prednisone) chemotherapy regimen was developed to treat patients with advanced HL following radiation ( Ansell, 2016 ; Vassilakopoulos and Johnson, 2016 ), and results in a long-term progression-free survival (PFS) rate of 54% and an overall survival (OS) rate of 48% ( Ansell, 2016 ). The combination of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) is currently the standard of treatment for HL around the world ( Chisesi et al, 2011 ; Corazzelli et al, 2011 ). ABVD was considered as a better option for HL therapy when compared to non-cross-resistant alternating regimens (MOPP + ABV [hybrid]: mechlorethamine + vincristine + procarbazine + prednisone + doxorubicin + bleomycin + vinblastine, as it was associated with a higher risk of secondary malignancy ( Souza et al, 2009 ).…”

“…ABVD was considered as a better option for HL therapy when compared to non-cross-resistant alternating regimens (MOPP + ABV [hybrid]: mechlorethamine + vincristine + procarbazine + prednisone + doxorubicin + bleomycin + vinblastine, as it was associated with a higher risk of secondary malignancy ( Souza et al, 2009 ). However, recent findings suggest that the BEACOPP (bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone) regimen is more effective in controlling advanced HL than ABVD ( Corazzelli et al, 2011 ). The dose-dense Stanford V (doxorubicin + vinblastine + mechlorethamine + vincristine + bleomycin + etoposide + prednisone) regimen was developed in the early 1990s, but ultimately failed to improve upon ABVD outcomes ( Chisesi et al, 2011 ; Vassilakopoulos and Johnson, 2016 ).…”

CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function

“…Hodgkin lymphoma is a highly curable disease in the current era. Chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD regimen) remains the mainstay of treatment [4,5,9,10]. As per American Cancer Society’s estimates for HL in the United States, the 5-year and 10-year survival rates reached 85% and 80%, respectively [11].…”

Image1.jpeg

“…ABVD was considered as a better option for HL therapy when compared to non-cross-resistant alternating regimens (MOPP + ABV [hybrid]: mechlorethamine + vincristine + procarbazine + prednisone + doxorubicin + bleomycin + vinblastine, as it was associated with a higher risk of secondary malignancy (Souza et al, 2009). However, recent findings suggest that the BEACOPP (bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone) regimen is more effective in controlling advanced HL than ABVD (Corazzelli et al, 2011). The dosedense Stanford V (doxorubicin + vinblastine + mechlorethamine + vincristine + bleomycin + etoposide + prednisone) regimen was developed in the early 1990s, but ultimately failed to improve upon ABVD outcomes (Chisesi et al, 2011;Vassilakopoulos and Johnson, 2016).…”